Floatz logo

Metarrestin

Pediatric Solid Tumor

National Cancer Institute (NCI)Small moleculePhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
89/ 100

Competitive context

19 Active assets in the Pediatric Solid Tumor cohort.

Asset / SponsorPhaseRating
Cyclophosphamide
Robbie Majzner
Phase 1/2CCC
Carboplatin
The Korean Society of Pediatric Hematology Oncology
Phase 2CCC
Pegteograstim
Samsung Medical Center
Phase 2CCC
(+)-VINCRISTINE
St. Jude Children's Research Hospital
Phase 1/2CCC
Irinotecan
St. Jude Children's Research Hospital
Phase 1/2CCC

View all 26 →

Same molecule, other indications

Metarrestin is also rated in:

malignant peripheral nerve sheath tumorDormant
CC
Indicative ·
43 / 100
View asset →
malignant pancreatic neoplasmDormant
C
Indicative ·
39 / 100
View asset →
breast cancerDormant
C
Indicative ·
39 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →